A novel stemness classification in acute myeloid leukemia by the stemness index and the identification of cancer stem cell-related biomarkers

Huang, Yue1; Zhang, Zhuo2,3; Sui, Meijuan4; Li, Yang5; Hu, Yi6; Zhang, Haiyu7; Zhang, Fan2

2023-06-19

10.3389/fimmu.2023.1202825

FRONTIERS IN IMMUNOLOGY   影响因子和分区

1664-3224

BackgroundStem cells play an important role in acute myeloid leukemia (AML). However, their precise effect on AML tumorigenesis and progression remains unclear. MethodsThe present study aimed to characterize stem cell-related gene expression and identify stemness biomarker genes in AML. We calculated the stemness index (mRNAsi) based on transcription data using the one-class logistic regression (OCLR) algorithm for patients in the training set. According to the mRNAsi score, we performed consensus clustering and identified two stemness subgroups. Eight stemness-related genes were identified as stemness biomarkers through gene selection by three machine learning methods. ResultsWe found that patients in stemness subgroup I had a poor prognosis and benefited from nilotinib, MK-2206 and axitinib treatment. In addition, the mutation profiles of these two stemness subgroups were different, which suggested that patients in different subgroups had different biological processes. There was a strong significant negative correlation between mRNAsi and the immune score (r= -0.43, p<0.001). Furthermore, we identified eight stemness-related genes that have potential to be biomarkers, including SLC43A2, CYBB, CFP, GRN, CST3, TIMP1, CFD and IGLL1. These genes, except IGLL1, had a negative correlation with mRNAsi. SLC43A2 is expected to be a potential stemness-related biomarker in AML. ConclusionOverall, we established a novel stemness classification using the mRNAsi score and eight stemness-related genes that may be biomarkers. Clinical decision-making should be guided by this new signature in prospective studies.

AML cancer stem cell mRNAsi biomarkers

SCI

英语

其他

National Natural Science Foundation of China[82003553] ; National Natural Science Foundation of Heilongjiang Province[LH2021H052] ; Postdoctoral Initiation Foundation of Heilongjiang Province["LBH-Z19179","LBH-Z18223"] ; Research Project of the First Affiliated Hospital of Harbin Medical University["2021Y04","2020YQ0004"] ; Scientific Research Start-up Project of Southern University of Science and Technology Hospital[2021005]

Immunology

Immunology

WOS:001021256400001

FRONTIERS MEDIA SA

Web of Science

1.Harbin Med Univ, Sch Publ Hlth, Dept Biostat, Harbin, Peoples R China
2.Harbin Med Univ, Natl Hlth Commiss NHC Key Lab Cell Transplantat, Affiliated Hosp 1, Harbin, Peoples R China
3.Southern Univ Sci & Technol Hosp, Dept Hematol, Shenzhen, Peoples R China
4.Harbin Med Univ, Key Lab Hepatosplen Surg, Minist Educ, Affiliated Hosp 1, Harbin, Peoples R China
5.Harbin Med Univ, Med Insurance Off, Affiliated Hosp 1, Harbin, Peoples R China
6.Harbin Inst Technol, Fac Comp, Ctr Bioinformat, Harbin, Heilongjiang, Peoples R China
7.Harbin Med Univ, Key Lab Cardiovasc Dis Acousto Opt Electromagnet D, Affiliated Hosp 1, Harbin, Peoples R China

Huang, Yue,Zhang, Zhuo,Sui, Meijuan,et al. A novel stemness classification in acute myeloid leukemia by the stemness index and the identification of cancer stem cell-related biomarkers[J]. FRONTIERS IN IMMUNOLOGY,2023,14.

Huang, Yue.,Zhang, Zhuo.,Sui, Meijuan.,Li, Yang.,Hu, Yi.,...&Zhang, Fan.(2023).A novel stemness classification in acute myeloid leukemia by the stemness index and the identification of cancer stem cell-related biomarkers.FRONTIERS IN IMMUNOLOGY,14.

Huang, Yue,et al."A novel stemness classification in acute myeloid leukemia by the stemness index and the identification of cancer stem cell-related biomarkers".FRONTIERS IN IMMUNOLOGY 14(2023).